Woippy, the 18th of November 2025 at 06.00 pm CET – ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce that the company presented four scientific posters last week at the AMP 2025 Congress in Boston, showcasing new data across its infectious-disease next-generation sequencing (NGS) platform and workflow solutions. These presentations highlight ABLD’s commitment to advancing research in sequencing technologies for pathogen genotyping and antimicrobial resistance studies.
Following the strong interest generated during AMP and the robust research performance demonstrated across multiple sequencing platforms, ABL Diagnostics is excited to collaborate with U.S. research institutions and academic centers. Our focus is on advancing scientific discovery through next-generation sequencing (NGS) genotyping and multiplexed microbial sequencing technologies, offered strictly for research use only and not for use in diagnostic procedures.
With the successful research verification of our sequencing workflows across leading NGS platforms, ABL Diagnostics is ready to collaborate with U.S. research organizations and academic centers to support advanced scientific studies.
- cost-efficient pooled sequencing for research projects,
- streamlined multiplex NGS workflows,
- flexible compatibility with multiple platforms,
- robust genotyping and resistance analysis for exploratory research.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer